Compare Quest Diagnostics Inc (DGX) vs Raytheon Technologies Corp (RTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Raytheon Technologies Corp — how do they compare? Quest Diagnostics Inc trades at $205.45 (market cap $22.80B), while Raytheon Technologies Corp trades at $193.93 (market cap $260.44B). The key difference: Raytheon Technologies Corp is far larger — about 11.4× Quest Diagnostics Inc's market cap, and Quest Diagnostics Inc pays the higher dividend (1.67%). Which is the better fit depends on your goals.
| DGX | RTX | |
|---|---|---|
Market Cap | $22.80B | $260.44B |
Sector | Health | Industrials |
52-Week High | $216.02 | $212.16 |
52-Week Low | $166.42 | $148.68 |
Enterprise Value | $28.82B | $292.55B |
Dividend Yield | 1.67% | 1.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
RTX trades at $193.39, down 1.3% on the day, with a bullish technical signal from moving averages and strong institutional support. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $1.78 exceeding expectations of $1.51. Revenue grew to $88.60 billion in 2025, and net income margin improved to 8.03%. Recent contract wins, including a $515 million U.S. Navy radar award announced June 3, 2026, underscore its defense sector strength.
Outlook remains positive given earnings momentum and defense budget tailwinds, but valuation at a P/E of 36.85 poses a risk if growth slows. Analyst consensus price target of $213.00 suggests 10% upside, with no sell ratings among 26 coverage firms. Key risks include execution on production targets and geopolitical shifts affecting defense spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Raytheon Technologies Corp
Raytheon Technologies is a diversified aerospace and defense industrial company formed from the merger of United Technologies and Raytheon, with roughly equal exposure as a supplier to commercial aerospace manufactures and to the defense market as a prime and subprime contractor.
Read more on RTX →
